Yarbrough Capital’s AbbVie ABBV Stock Holding History

Yarbrough Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,080	Closed	-$247K	–	86
2025 Q4	$247K	Buy	+1,080	New	+$246K	0.01%	152

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Yarbrough Capital's ABBV Position: Q1 2026 in Review

Yarbrough Capital sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,080 shares — an estimated $247K sold.

Yarbrough Capital first reported a position in ABBV in Q4 2025 and held it in 1 quarter. The position peaked at $247K in Q4 2025. 4,097 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Yarbrough Capital reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Yarbrough Capital sold 1,080 AbbVie shares in Q1 2026, an estimated $247K.
Yarbrough Capital first reported a position in AbbVie in Q4 2025 and held it in 1 quarter.
Yarbrough Capital's AbbVie position peaked at $247K in Q4 2025.
4,097 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Yarbrough Capital's 13F filing for Q1 2026, filed 14 Apr 2026.